![Ken Drazan](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Ken Drazan
Algemeen Directeur bij
Arsenal Biosciences, Inc.
Profiel
Ken E.
Drazan is the founder of Arsenal Biosciences, Inc., founded in 2019, where the title held is Chairman & Chief Executive Officer.
Dr. Drazan is also the founder of ArgiNOx Pharmaceuticals, Inc...
Dr. Drazan currently works at Stanford University as a Surgeon.
Former jobs include Executive Chairman at GENASCIS LLC, Basic Scientist at the University of California, Los Angeles, General Partner at Bertram Capital Management LLC from 2010 to 2011, and President at GRAIL, Inc. Education includes undergraduate studies at Yale University and a doctorate from The State University of New York.
Actieve functies van Ken Drazan
| Bedrijven | Functie | Begin |
|---|---|---|
Stanford University
 Stanford University Other Consumer ServicesConsumer Services Functions as a College/University | Corporate Officer/Principal | - |
Arsenal Biosciences, Inc.
 Arsenal Biosciences, Inc. BiotechnologyHealth Technology Operates as a clinical stage and programmable cell therapy company focused on solid tumor cell therapies to defeat cancer | Algemeen Directeur | 01-01-2019 |
Eerdere bekende functies van Ken Drazan
| Bedrijven | Functie | Einde |
|---|---|---|
| GRAIL, INC. | President | 01-08-2018 |
GENASCIS LLC
 GENASCIS LLC Packaged SoftwareTechnology Services Provides revenue cycle management services for ambulatory surgery centers | Voorzitter | - |
Bertram Capital Management LLC
 Bertram Capital Management LLC Investment ManagersFinance Bertram Capital Mgmt invests in middle-market companies located in the United States with an enterprise value of USD 50 - 500 million, an EBITDA of USD 5 - 35 million and revenues of USD 20 - 250 million. The firm focuses on sectors such as business services, consumer, industrial/manufacturing and technology. It participates in divestitures, MBO, shareholder liquidity events with an investment size of USD 25 - 250 million. The firm acquires controlling interests. | Private Equity Investor | - |
University of California, Los Angeles
 University of California, Los Angeles Other Consumer ServicesConsumer Services Functions as a College/University | Corporate Officer/Principal | - |
ArgiNOx Pharmaceuticals, Inc.
 ArgiNOx Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Develops pharmaceutical products | Oprichter | - |
Opleiding van Ken Drazan
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
96
Eerstegraads connecties
9
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Bedrijven in privébezit | 9 |
|---|---|
ArgiNOx Pharmaceuticals, Inc.
ArgiNOx Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Develops pharmaceutical products | Health Technology |
Stanford University
Stanford University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
University of California, Los Angeles
University of California, Los Angeles Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Yale University
 Yale University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
The State University of New York
 The State University of New York Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Bertram Capital Management LLC
Bertram Capital Management LLC Investment ManagersFinance Bertram Capital Mgmt invests in middle-market companies located in the United States with an enterprise value of USD 50 - 500 million, an EBITDA of USD 5 - 35 million and revenues of USD 20 - 250 million. The firm focuses on sectors such as business services, consumer, industrial/manufacturing and technology. It participates in divestitures, MBO, shareholder liquidity events with an investment size of USD 25 - 250 million. The firm acquires controlling interests. | Finance |
GENASCIS LLC
GENASCIS LLC Packaged SoftwareTechnology Services Provides revenue cycle management services for ambulatory surgery centers | Technology Services |
GRAIL, Inc.
 GRAIL, Inc. Medical SpecialtiesHealth Technology Manufactures cancer detection test kits and provides related services | Health Technology |
Arsenal Biosciences, Inc.
Arsenal Biosciences, Inc. BiotechnologyHealth Technology Operates as a clinical stage and programmable cell therapy company focused on solid tumor cell therapies to defeat cancer | Health Technology |
